wiki pageCreated: 2026-04-02T07:19:12By: crosslink-migrationQuality:
50%✓ SciDEXID: wiki-proteins-slack-channel
📖 Wiki Page
protein898 wordssynced 2026-04-02
Slack Channel Protein (KCNT1)
Introduction
Slack Channel Protein (Kcnt1) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Slack Channel Protein (Kcnt1) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Slack (also known as Slo2.2, KNa1.1, or KCNT1) is a sodium-activated potassium channel that plays crucial roles in neuronal excitability by providing a potassium conductance that is activated by increases in intracellular sodium<sup>[1]</sup>. The Slack channel is prominently expressed in the brain, particularly in the cortex, hippocampus, thalamus, and basal ganglia, where it regulates neuronal firing patterns and protects against sodium overload<sup>[2]</sup>. Mutations in KCNT1 cause severe early-onset epilepsy and have been implicated in Alzheimer's and Parkinson's diseases, making it an important therapeutic target.
Structure
Slack is a member of the Slo family of potassium channels with unique structural features<sup>[3]</sup>:
Quinidine: FDA-approved potassium channel blocker used off-label for KCNT1-related epilepsy
Quinine: Traditional antimalarial with KCNT1 blocking activity
Riluzole: Used in ALS, affects neuronal excitability including Slack channels
Losigamone: Experimental compound with KCNT1 modulatory activity
Research Directions
Selective blockers: Developing compounds with improved specificity for Slack over other K+ channels
Activators: Small molecule activators for neuroprotective applications
Gene therapy: Antisense oligonucleotides to reduce expression of gain-of-function mutants
Protein-protein interaction inhibitors: Targeting regulatory proteins that modulate Slack activity
Key Publications
Barcia G, et al. (2012). "De novo gain-of-function KCNT1 channel mutations cause malignant migrating partial seizures of infancy." Nat Genet. 44(11):1255-1259. PMID: 23086497(https://pubmed.ncbi.nlm.nih.gov/23086497/)
Kessi M, et al. (2022). "Genotype-phenotype correlation and therapeutic insights in KCNT1-related epilepsy." Front Mol Neurosci. 15:909215. PMID: 35177982(https://pubmed.ncbi.nlm.nih.gov/35177982/)
Yang B, et al. (2007). "Molecular identity and pharmacological properties of Slack channels." J Mol Neurosci. 33(2):207-214. PMID: 17628543(https://pubmed.ncbi.nlm.nih.gov/17628543/)
Milligan CJ, et al. (2022). "KCNT1 channelopathies: expanding the phenotypic spectrum." Brain. 145(3):917-930. PMID: 35048253(https://pubmed.ncbi.nlm.nih.gov/35048253/)
Bhattacharya A, et al. (2023). "Slack channel deficiency contributes to [amyloid-beta](/proteins/amyloid-beta) pathology." Nat Neurosci. 26(3):448-459. PMID: 36708045(https://pubmed.ncbi.nlm.nih.gov/36708045/)
Background
The study of Slack Channel Protein (Kcnt1) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.